| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial
|
de Steur, W.O.
|
|
|
32 |
3 |
p. 360-367
|
article
|
| 2 |
Adjuvant radiotherapy for gastric cancer—end of the road?
|
Lordick, F.
|
|
|
32 |
3 |
p. 287-289
|
article
|
| 3 |
A prospective study of type 2 diabetes, metformin use, and risk of breast cancer
|
Park, Y.-M.M.
|
|
|
32 |
3 |
p. 351-359
|
article
|
| 4 |
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆
|
Park, S.H.
|
|
|
32 |
3 |
p. 368-374
|
article
|
| 5 |
Cobimetinib plus atezolizumab in BRAF V600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
|
Gogas, H.
|
|
|
32 |
3 |
p. 384-394
|
article
|
| 6 |
Corrigendum to ‘Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases’
|
Aljubran, A.H.
|
|
|
32 |
3 |
p. 424
|
article
|
| 7 |
Diabetes, metformin and breast cancer: a tangled web
|
Lohmann, A.E.
|
|
|
32 |
3 |
p. 285-286
|
article
|
| 8 |
Editorial Board
|
|
|
|
32 |
3 |
p. iii
|
article
|
| 9 |
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
|
Belli, C.
|
|
|
32 |
3 |
p. 337-350
|
article
|
| 10 |
Follicular lymphoma: treatment guidance in times of change
|
Buske, C.
|
|
|
32 |
3 |
p. 293-294
|
article
|
| 11 |
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
|
Franzoi, M.A.
|
|
|
32 |
3 |
p. 323-336
|
article
|
| 12 |
Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy
|
Grinshpun, A.
|
|
|
32 |
3 |
p. 423
|
article
|
| 13 |
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Dimopoulos, M.A.
|
|
|
32 |
3 |
p. 309-322
|
article
|
| 14 |
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † ☆
|
Dreyling, M.
|
|
|
32 |
3 |
p. 298-308
|
article
|
| 15 |
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer
|
Powles, T.
|
|
|
32 |
3 |
p. 422-423
|
article
|
| 16 |
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
|
Sznol, M.
|
|
|
32 |
3 |
p. 295-297
|
article
|
| 17 |
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†
|
Cottereau, A.-S.
|
|
|
32 |
3 |
p. 404-411
|
article
|
| 18 |
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
|
Perets, R.
|
|
|
32 |
3 |
p. 395-403
|
article
|
| 19 |
Sentinel node biopsy for primary cutaneous melanoma
|
Faries, M.B.
|
|
|
32 |
3 |
p. 290-292
|
article
|
| 20 |
Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor
|
El Sharouni, M.-A.
|
|
|
32 |
3 |
p. 375-383
|
article
|
| 21 |
Table of Contents
|
|
|
|
32 |
3 |
p. i-ii
|
article
|
| 22 |
The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin
|
Hernando, B.
|
|
|
32 |
3 |
p. 412-421
|
article
|
Journal description